What lies ahead India’s oncology tests market?

The market faces several challenges related to access, affordability, and tech adoption.

India’s oncology tests market is projected to grow at a compound annual growth rate of around 2% through 2033, according to GlobalData.

The country accounted for over 3% of the Asia-Pacific oncology tests market in 2024. Its expansion is attributed to the rising demand for advanced oncology diagnostic and treatment services due to the significant social and healthcare burden of cancer.

However, the market faces several challenges related to access, affordability, and technological adoption, said Shreya Jain, Medical Devices Analyst at GlobalData.

“Because of inadequate infrastructure and expertise, the adoption and integration of new approaches like AI-assisted diagnostics, precision medicine, and minimally invasive therapies are low,” the analyst said.

Meanwhile, a recent development is the launch of Bengaluru-based Strand Life Sciences’s  “CancerSpot”, a blood-based test that utilises methylation profiling technology for the early detection of multiple cancers.

“Tailored diagnostics, like genomic tests calibrated for Indian cohorts, can enhance early detection accuracy, improve risk stratification, and ensure that treatments align with the unique genetic profiles of Indian patients,” Jain added.